Connecticut v. Sandoz, Inc.

CourtDistrict Court, D. Connecticut
DecidedNovember 12, 2024
Docket3:20-cv-00802
StatusUnknown

This text of Connecticut v. Sandoz, Inc. (Connecticut v. Sandoz, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Connecticut v. Sandoz, Inc., (D. Conn. 2024).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

THE STATE OF CONNECTICUT; THE STATE OF ALASKA; THE STATE OF ARIZONA; THE STATE OF ARKANSAS; THE STATE OF CALIFORNIA; No. 3:20-cv-00820 (MPS) THE STATE OF COLORADO; THE STATE OF DELAWARE; THE DISTRICT OF COLUMBIA; THE STATE OF FLORIDA; THE STATE OF GEORGIA; THE TERRITORY OF GUAM; THE STATE OF HAWAII; THE STATE OF IDAHO; THE STATE OF ILLINOIS; THE STATE OF INDIANA; THE STATE OF IOWA; THE STATE OF KANSAS; THE COMMONWEALTH OF KENTUCKY; THE STATE OF LOUISIANA; THE STATE OF MAINE; THE STATE OF MARYLAND; THE COMMONWEALTH OF MASSACHUSETTS; THE STATE OF MICHIGAN; THE STATE OF MINNESOTA; THE STATE OF MISSISSIPPI; THE STATE OF MISSOURI; THE STATE OF MONTANA; THE STATE OF NEBRASKA; THE STATE OF NEVADA; THE STATE OF NEW HAMPSHIRE; THE STATE OF NEW JERSEY; THE STATE OF NEW MEXICO; THE STATE OF NEW YORK; THE STATE OF NORTH CAROLINA; THE STATE OF NORTH DAKOTA; THE COMMONWEALTH OF THE NORTHERN MARIANA ISLAND; THE STATE OF OHIO; THE STATE OF OKLAHOMA; THE STATE OF OREGON; THE COMMONWEALTH OF PENNSYLVANIA; THE COMMONWEALTH OF PUERTO RICO; THE STATE OF RHODE ISLAND; THE STATE OF SOUTH CAROLINA; THE STATE OF TENNESSEE; THE STATE OF UTAH; THE STATE OF VERMONT; THE COMMONWEALTH OF VIRGINIA; THE STATE OF WASHINGTON; THE STATE OF WEST VIRGINIA; THE STATE OF WISCONSIN; and U.S. VIRGIN ISLANDS

v.

SANDOZ, INC.; ACTAVIS HOLDCO US, INC.; ACTAVIS ELIZABETH LLC; ACTAVIS PHARMA, INC.; AMNEAL PHARMACEUTICALS, INC.; AMNEAL PHARMACEUTICALS, LLC; ARA APRAHAMIAN; AUROBINDO PHARMA U.S.A., INC.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH US, LLC; MITCHELL BLASHINSKY; DOUGLAS BOOTHE; FOUGERA PHARMACEUTICALS INC.; GLENMARK PHARMACEUTICALS INC., USA; JAMES (JIM) GRAUSO; GREENSTONE LLC; G&W LABORATORIES, INC.; WALTER KACZMAREK; ARMANDO KELLUM; LANNETT COMPANY, INC.; LUPIN PHARMACEUTICALS, INC.; MALLINCKRODT INC.; MALLINCKRODT LLC; MALLINCKRODT plc; MYLAN INC.; MYLAN PHARMACEUTICALS INC.; KURT ORLOFSKI; MICHAEL PERFETTO; PERRIGO NEW YORK, INC.; PFIZER INC.; SUN PHARMACEUTICAL INDUSTRIES, INC.; TARO PHARMACEUTICALS USA, INC.; TELIGENT, INC.; ERIKA VOGEL- BAYLOR; JOHN WESOLOWSKI; and WOCKHARDT USA LLC

RULING ON MOTION TO DISMISS STATE-LAW CLAIMS The Defendants, thirty-six makers of generic drugs, have moved under Fed. R. Civ. P. 12(b)(6) to dismiss state-law claims asserted by the Plaintiffs, the Attorneys General of most of the States and certain U.S. Territories, in this sprawling action alleging price-fixing, market allocation, and bid rigging in the sale of generic drugs for skin ailments. For the reasons set forth below, I grant in part and deny in part the Defendants’ motion. I. Introduction A. Procedural Background This is one of three cases in which the Attorneys General of the States and territories have sued scores of generic drug makers for alleged antitrust violations and unfair trade practices. All three cases were originally filed in this Court but were transferred to the Eastern District of Pennsylvania (the “MDL Court”), which was designated by the Judicial Panel on Multi-district Litigation (the “JPMDL) to preside over these and other similar cases brought by private parties in a consolidated proceeding. ECF No. 9.1 In April, the JPMDL remanded these three cases to this Court, and they were assigned to me. ECF No. 11.

B. Allegations The operative complaint in this case, the September 9, 2021 amended complaint (ECF No. 196 on this Court’s docket), spans 609 pages and includes 2,123 numbered paragraphs. It alleges collusion in the pricing, market allocation, and bidding for generic drugs for dermatological applications. (The parties refer to it as the “the Dermatology Complaint.”) The complaint describes a series of conspiracies, and an overarching conspiracy, between makers of generic dermatological drug-related products to collude on price, market allocation, and bids for the business of customers. For example, the complaint alleges that generic drug makers “had long-standing agreements over the course of several years not to compete for each other’s customers and to follow each other’s price increases” and that “to maintain these unlawful

agreements, the competitors stayed in nearly constant communication—meeting regularly at trade shows and customer conferences and communicating frequently by phone and text message to reinforce their understandings.” ECF No. 196 at 15. The complaint claims that these agreements were endemic in the generic drug industry as a whole: “For many years, the larger generic pharmaceutical industry has operated pursuant to an overarching understanding to avoid competing with each other and to instead settle for what these competitors refer to as their ‘fair

1 Unless otherwise indicated, all ECF numbers in this ruling refer to entries on the docket of this case, not the same case when it was before the MDL court, and each page number refers to the page number shown on the ECF stamp on the top of the cited page, not the page of the relevant brief or pleading designated by the parties. share.’ This understanding has permeated every segment of the industry, and the purpose of the agreement was to avoid competition among generic manufacturers that would normally result in lower prices and greater savings to the ultimate consumer.” Id. at 16. The complaint goes on to discuss the structure of the industry and to allege in detail a myriad of specific communications

between competitors in the segment concerning skin products. See also In re Generic Pharms. Pricing Antitrust Litig., No. 16-md-2724, 2023 WL 2244685, at *1 (E.D. Pa. Feb. 27, 2023) (briefly summarizing allegations in Dermatology Complaint). Because the factual details of the alleged agreements are not critical to this ruling for reasons I explain below, however, I do not further summarize the complaint here. C. Rule 12(b)(6) While the Defendants have filed previous motions attacking the federal antitrust claims in this case, this motion targets only the States’ state-law claims and, as discussed below, only certain portions of those claims. In federal court, each complaint must include “a short and plain statement of the claim showing that the pleader is entitled to relief,” Fed. R. Civ. 8(a)(2), and if

the complaint “fail[s] to state a claim upon which relief can be granted,” Fed. R. Civ. P. 12(b)(6), the court must dismiss it. In deciding the Defendants’ motion to dismiss under Rule 12(b)(6), I must determine whether the States have alleged “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). I must accept as true the complaint’s factual allegations, id., and must “draw all reasonable inferences in favor of the non-moving party,” Vietnam Ass’n for Victims of Agent Orange v. Dow Chem. Co., 517 F.3d 104, 115 (2d Cir. 2008), but “threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice” to survive a motion to dismiss. Mastafa v. Chevron Corp., 770 F.3d 170, 177 (2d Cir. 2014) (citation omitted). For the most part, however, the Defendants’ motion does not involve the application of

these standards—making it an unusual Rule 12(b)(6) motion.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United Mine Workers of America v. Gibbs
383 U.S. 715 (Supreme Court, 1966)
Illinois Brick Co. v. Illinois
431 U.S. 720 (Supreme Court, 1977)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. St. Regis Paper Co.
285 F.2d 607 (Second Circuit, 1960)
In Re Irving L. GARTENBERG, Petitioner
636 F.2d 16 (Second Circuit, 1980)
Hindes v. Federal Deposit Insurance Corporation
137 F.3d 148 (Third Circuit, 1998)
State of Mississippi v. AU Optronics Corporation
701 F.3d 796 (Fifth Circuit, 2012)
Freeman Industries, LLC v. Eastman Chemical Co.
172 S.W.3d 512 (Tennessee Supreme Court, 2005)
Hyde v. Abbott Laboratories, Inc.
473 S.E.2d 680 (Court of Appeals of North Carolina, 1996)
Madera v. State Industrial Insurance System
956 P.2d 117 (Nevada Supreme Court, 1998)
Hunt v. United States Tobacco Co.
538 F.3d 217 (Third Circuit, 2008)
Griffith v. Bank of New York
147 F.2d 899 (Second Circuit, 1945)
Sickles v. Cabot Corp.
877 A.2d 267 (New Jersey Superior Court App Division, 2005)
Commonwealth v. Karetny
880 A.2d 505 (Supreme Court of Pennsylvania, 2005)
Eugene Dietzgen Co. v. Federal Trade Commission
142 F.2d 321 (Seventh Circuit, 1944)

Cite This Page — Counsel Stack

Bluebook (online)
Connecticut v. Sandoz, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/connecticut-v-sandoz-inc-ctd-2024.